购物车
- 全部删除
- 您的购物车当前为空
L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) 是一种 TWEAK-Fn14 信号级联抑制剂。
为众多的药物研发团队赋能,
让新药发现更简单!
L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) 是一种 TWEAK-Fn14 信号级联抑制剂。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,297 | 现货 | |
2 mg | ¥ 1,939 | 现货 | |
5 mg | ¥ 2,927 | 现货 | |
10 mg | ¥ 4,388 | 现货 | |
25 mg | ¥ 7,320 | 现货 | |
50 mg | ¥ 9,870 | 现货 | |
100 mg | ¥ 13,300 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 2,770 | 现货 |
产品描述 | L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) is a TWEAK-Fn14 signaling cascade inhibitor. |
体外活性 | L524-0366通过TAC减轻了不良重塑。TWEAK通过部分激活非典型NF-κB信号传导,诱导了来自WT但不是Fn14-/-纤维细胞的促炎症趋化因子,单核细胞趋化蛋白1的分泌。最终,在TAC后的小鼠以及人类衰竭心脏中,发现Fn14表达增加。 |
细胞实验 | Wild type (WT) and Fn14 knock out (Fn14-/-) mice were subjected to pressure overload [transaortic constriction (TAC)] for 1 or 6 weeks. A subset of WT TAC animals were treated with the Fn14 antagonist L524-0366. Cardiac function was measured by echocardiography. Cardiac fibrosis and macrophage infiltration were quantified using immunohistochemistry and flow cytometry, respectively. Cardiac fibroblasts were isolated for quantifying TWEAK-induced chemokine release. |
别名 | [1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone |
分子量 | 308.79 |
分子式 | C13H13ClN4OS |
CAS No. | 951612-19-4 |
存储 | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | 5% DMSO+95% Corn oil: 1 mg/mL (3.24 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. DMSO: 25 mg/ml (80.96 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
5% DMSO+95% Corn oil/DMSO
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.